Medication info
Gabamed Capsule 25 mg (Pregabalin)

Gabamed Capsule 25 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
NBK Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a light yellow upper part and a white lower part containing white powder
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 202000452 · Approved 2020.01.29 · Insurance code 054800630

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x weight (kg) 72 x serum creatinine (mg/dL) * For women, multiply the result obtained from the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration method Initial dose (mg/day) Maximum dose (mg/day) ≥60: initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under administration method. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
Administration is not recommended in children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
NBK Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine effectively treats peripheral and central neuropathic pain in adults. It is also used as an adjunct for patients with epilepsy who have either secondary generalized symptoms or partial seizures. Additionally, it helps relieve pain associated with fibromyalgia. It is widely used for improving the symptoms of various neurological diseases.

Dosage and Administration

Adult dosage

This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x weight (kg) 72 x serum creatinine (mg/dL) * For women, multiply the result obtained from the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration method Initial dose (mg/day) Maximum dose (mg/day) ≥60: initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under administration method. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

Administration is not recommended in children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so if mood changes or abnormal behavioral changes occur during treatment, it's important to inform a healthcare professional immediately. Patients with allergies to any of the ingredients in this drug, or those with specific genetic issues such as lactose intolerance, should not take it. Diabetic patients should be cautious as weight gain associated with this medication may necessitate adjustments in blood glucose control medication doses. If symptoms of angioedema occur, use of the medication should be stopped immediately. Elderly patients should be careful due to the risk of falls from dizziness or drowsiness. Blurred vision or changes in vision may occur, so consult a healthcare provider if these symptoms arise. Suddenly stopping this medication can lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be tapered off gradually following a doctor's instruction. Due to the risk of drug abuse, patients with a history of mental illness or substance abuse should exercise particular caution. Patients with reduced kidney function should have their doses adjusted, and those with heart disease should take this medication carefully. Co-administration with drugs that have central nervous system depressant effects may increase the risk of respiratory depression, so caution is required. During early pregnancy, there is a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant should consult a physician before taking this medication and use effective contraception. Breastfeeding women should consider that the drug may be excreted in breast milk, with safety for infants not established, hence stopping breastfeeding or discontinuing the medication should be considered. Activities that require attention, such as driving or operating machinery, should be avoided until dizziness or drowsiness has resolved after taking this medication. An overdose may result in confusion, drowsiness, and depression; in severe cases, emergency treatment such as dialysis may be required. Keep out of reach of children and do not transfer the medication to other containers for safety.

Side effects

  • suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial edema
  • periorbital edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 174 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle contractions
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • abnormal sensations
  • fatigue
  • tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • reduced serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • rhinopharyngitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • restlessness
  • mood swings
  • emotional flatness
  • elevation of mood
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention deficit disorder
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • position-related dizziness
  • hypersensitivity
  • burning sensation
  • tremor with activity
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing dysfunction
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • respiratory distress
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue edema
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • exacerbation of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a light yellow upper part and a white lower part containing white powder

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.